Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
228.24
-0.49 (-0.21%)
At close: Apr 1, 2026, 4:00 PM EDT
225.80
-2.44 (-1.07%)
After-hours: Apr 1, 2026, 7:30 PM EDT
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
$711,121
Profits / Employee
-$225,181
Market Cap
14.01B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,189 | 172 | 16.91% |
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Dec 31, 2022 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | 216 | 79 | 57.66% |
| Dec 31, 2017 | 137 | 36 | 35.64% |
| Dec 31, 2016 | 101 | 23 | 29.49% |
| Dec 31, 2015 | 78 | 23 | 41.82% |
| Dec 31, 2014 | 55 | 10 | 22.22% |
| Dec 31, 2013 | 45 | 7 | 18.42% |
| Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 2,973 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Ionis Pharmaceuticals | 1,402 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| Revolution Medicines | 883 |
ASND News
- 15 days ago - New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 - GlobeNewsWire
- 16 days ago - New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026 - GlobeNewsWire
- 20 days ago - Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity - Seeking Alpha
- 4 weeks ago - Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 4 weeks ago - Ascendis Pharma: Yuviwel Approved Despite Legal Challenges - Seeking Alpha
- 4 weeks ago - Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript - Seeking Alpha
- 4 weeks ago - Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 4 weeks ago - Ascendis wins U.S. approval for therapy for children with dwarfism - Reuters